




TECHNOLOGY

Wnt Signaling Inhibitors for the Treatment of Diabetes

OVERVIEW

The Wnt/ β -catenin signaling pathway plays a pivotal role in cell proliferation and differentiation through the regulation of the transcriptional factor β -catenin. The Wnt pathway has been studied extensively for cancer (colon, liver) but the role of the Wnt/ β -catenin signaling pathway in diabetes is unknown. UMB researchers have discovered the effect of pyrvinium pamoate to inhibit the Wnt pathway in diabetic mouse models. This technology is a set of novel Wnt/ β -catenin signaling inhibitors based on the pyrvinium pamoate structure and their method of use for the treatment of diabetes.

Pyrvinium pamoate, a FDA approved, anthelmintic drug for the treatment of *Enterobius vermicularis* (pinworms), was identified as a potent Wnt/ β -catenin pathway inhibitor. Initial proof of concept studies confirmed that pyrvinium injection could significantly improve glucose tolerance and decrease body weight gain in mice fed on a high-fat diet. However, to increase the potency, metabolic stability, and bioavailability of pyrvinium pamoate, novel analogs of pyrvinium pamoate were generated and the lead candidate, YW1149, was identified. Currently, no Wnt/ β -catenin pathway inhibitors are clinically available for targeted therapy.



APPLICATIONS

The global prevalence of diabetes among adults over 18 years has risen from 4.7% in 1980 to 8.5% in 2014. In 2015, an estimated 1.6 million deaths were directly caused by diabetes and another 2.2 million deaths were attributable to high blood glucose in 2012. Due to the widespread reach of the disease, the diabetes market continues to grow. New antidiabetic drugs continue to be developed but older classes of drugs and generics are still widely being used. However, diabetes treatments often lose effectiveness after extended use and require a change in drug or a treatment must be added to the patient's regimen to manage the chronic disease. The role of the Wnt pathway has been validated for cancer (colon, liver) therapy target, but its role in diabetes is a potential novel target.

ADVANTAGES

Novel, potent inhibitor of the Wnt/ β -catenin pathway with increased bioavailability and metabolic stability.

STAGE OF DEVELOPMENT

Ongoing *in vivo* studies with lead compound

LICENSING POTENTIAL

Available for licensing

CONTACT INFO

Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: ott@umaryland.edu
Phone: (410) 706-2380

Additional Information

INSTITUTION

University of Maryland, Baltimore

PATENT STATUS

PCT Patent Application, filed

LICENSE STATUS

Available for licensing

INVESTIGATOR(S)

Fengtian Xue
Yan Shu

ATTACHMENTS

-  [Download FX-2015-082 marketing summary.pdf](#)

FX-2015-082